Forte Biosciences
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 9
- Market Cap
- -
- Website
- http://www.fortebiorx.com
- Introduction
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner in 2017 and is headquartered in Dallas, TX.
Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)β’ Click on a phase to view related trials
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
- First Posted Date
- 2025-10-03
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Forte Biosciences, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT07205159
- Locations
- π¦πΊ
St Leonards, Saint Leonards, New South Wales (nsw), Australia
π¦πΊCoorparoo, Coorparoo, Queensland, Australia
π¦πΊSouth Yarra, South Yarra, Victoria, Australia
Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Forte Biosciences, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06982963
- Locations
- π¦πΊ
The Royal Melbourne Hospital, Melbourne, Australia
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Forte Biosciences, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06905873
- Locations
- π¦πΊ
Skin & Cancer Foundation Australia - The Skin Hospital, Darlinghurst, New South Wales, Australia
π¦πΊNovatrials, Kotara, New South Wales, Australia
π¦πΊCornerstone Dermatology, Coorparoo, Queensland, Australia
Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Forte Biosciences, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04936113
- Locations
- πΊπΈ
Center for Dermatology Clinical Research, Inc., Fremont, California, United States
πΊπΈMulti-Specialty Research Associates, Inc., Lake City, Florida, United States
πΊπΈMedaPhase, Inc, Newnan, Georgia, United States
Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Forte Biosciences, Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT04504279
- Locations
- πΊπΈ
First OC Dermatology, Fountain Valley, California, United States
πΊπΈCenter for Dermatology Clinical Research, Inc., Fremont, California, United States
πΊπΈMulti-Specialty Research Associates, Inc., Lake City, Florida, United States
News
Vitiligo Treatment Pipeline Shows Promise with JAK Inhibitors and Novel Immunotherapies in Phase 3 Trials
Over 18 companies are actively developing 20+ pipeline therapies for vitiligo treatment, with JAK inhibitors leading the charge in late-stage clinical trials.